Comparative Pharmacology
Head-to-head clinical analysis: CHOLINE C 11 versus INDIUM IN 111 OXYQUINOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLINE C 11 versus INDIUM IN 111 OXYQUINOLINE.
CHOLINE C-11 vs INDIUM IN 111 OXYQUINOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choline C-11 is a radioactive diagnostic agent; after intravenous administration, it is taken up by cells and phosphorylated by choline kinase. It accumulates in tissues with high choline metabolism, such as tumors (e.g., prostate cancer), allowing positron emission tomography (PET) imaging. The mechanism for tumor uptake is related to increased cell membrane synthesis and choline kinase activity.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
Intravenous: 370-740 MBq (10-20 mCi) as a single injection for PET imaging. Dose depends on patient weight, camera sensitivity, and imaging protocol.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
None Documented
None Documented
The terminal elimination half-life of [11C]choline in plasma is approximately 5-10 minutes. This short half-life is consistent with its use as a PET imaging agent, allowing same-day imaging without significant residual radiation exposure.
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Primarily renal excretion; approximately 70-80% of administered radioactivity is eliminated in urine within 2 hours, with less than 5% fecal elimination.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical